News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cord Blood America CEO Matthew Schissler In Investor Presentation Says CBAI Is A Leader Among Micro-Cap Stem Cell Companies In Financial Performance



10/2/2006 12:44:49 PM

LOS ANGELES, and LAS VEGAS, Oct. 2 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. Chairman and CEO Matthew L. Schissler will be presenting on Tuesday, October 3, 2006, at the Fall 2006 Global Equities Conference and will highlight Cord Blood America as a leader among micro-cap stem cell companies in almost every financial performance measurement. Cord Blood America is the umbilical cord blood stem cell preservation company, focused on bringing the life saving potential of stem cells to families nationwide.

"CBAI outperforms micro-cap stem cell companies in almost every key financial statistic commonly analyzed by Wall Street. Yet our share price and market cap has not caught up to these other statistics, which is a key indicator to us that we need to do a better job of telling our story. The presentation in Las Vegas is a first key step in re-engaging the market with CBAI successes."

Mr. Schissler will also speak about significant growth indicators for this industry. "With less than five percent current market penetration among the four million births annually in the U.S., enormous opportunities exist for growth," Mr. Schissler will say. He will tell the Las Vegas investment audience that it is estimated that this will be a $1 billion market by 2010.

Cord Blood America's CEO will also discuss the best strategy for growth, which he believes is accretive acquisitions, since there are currently 26 companies collecting umbilical cord blood.

"Cord Blood America is the top performer in 11 of 14 key financial categories analyzed in our upcoming presentation, and we will strongly emphasize to these potential investors the history of revenue growth and liquidity at our Company," Mr. Schissler said. "Future additional acquisitions by Cord Blood America may allow for strong stock uplift and a market cap increase." The presentation will be available beginning approximately 12 Noon Pacific at www.cordblood-america.com on Tuesday, October 3.

Cord Blood America's CEO will present at 10:40 a.m. Pacific on October 3, at the Hard Rock Hotel in Las Vegas. The conference is sponsored by Friedland Investment Events, the world's largest sponsor of financial and investment conferences.

About Cord Blood America

Cord Blood America is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. , visit our website at www.cordpartners.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com

Cord Blood America, Inc.

CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,pknopick@eandecommunications.com, for Cord Blood America, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES